SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*	2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name **and** Ticker or Trading Symbol
Fu Tao (Last) (First) (Middle) C/O ATTOVIA THERAPEUTICS, INC. 1091 INDUSTRIAL ROAD, SUITE 310 (Street) SAN CARLOS CA 94070 (City) (State) (Zip)	08/04/2026	Attovia Therapeutics, Inc. [ATTO] Foreign Trading Symbol

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)	5. If Amendment, Date of Original Filed (Month/Day/Year)
☑ Director ☐ 10% Owner ☑ Officer (give title below) ☐ Other (specify below) President and CEO	08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)
☑ Form filed by One Reporting Person
☐ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	87,843	D	
Common Stock	99,181	I	By Trust(1)
Common Stock	116,103	I	By Trust(2)
Common Stock	245,425	I	By Trust(3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(4)	08/16/2033	Common Stock	23,437	1.5793	D	
Stock Option (Right to Buy)	(5)	05/08/2034	Common Stock	409,709	3.5302	D	
Stock Option (Right to Buy)	(6)	05/17/2035	Common Stock	370,290	4.9237	D	

Explanation of Responses:

1. These shares are held by the TF 2025 Annuity Trust, of which the reporting person is the trustee.

2. These shares are held by the TF 2026 Annuity Trust, of which the reporting person is the trustee.

3. These shares are held by the Hai Fu Revocable Trust, of which the reporting person and Hai Fu are trustees.

4. Vest with respect to 25% of the shares of common stock underlying the stock option on the one year anniversary of June 2, 2023, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service through such date.

5. Vest with respect to 25% of the shares of common stock underlying the stock option on the one year anniversary of May 9, 2024, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service through such date.

6. Vest with respect to 25% of the shares of common stock underlying the stock option on the one year anniversary of May 18, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service through such date.

Remarks:

This Form 3 amendment amends the Form 3 filed on August 4, 2026, which reported the Reporting Person's beneficial ownership using the Issuer's CIK number. This Form 3 amendment has been filed under the Reporting Person's CIK and reflects him as the Reporting Person. This filing amends and replaces the original filing in its entirety. No changes have been made or are being reported with respect to the Reporting Person's beneficial ownership of the Issuer's securities.

/s/ Steven Chan, Attorney-in-Fact for Tao Fu — 10/08/2026

** Signature of Reporting — Date

Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints Steven Chan (an "***Attorney-in-Fact***"), as long as such individual is providing services to Attovia Therapeutics, Inc., a Delaware corporation (the "***Company***"), acting individually, as the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4, and 5, and any amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 (as amended, the "***Exchange Act***"), and the rules and regulations thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Forms 3, 4, and 5, and any amendments thereto, and file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority, if required; and

(3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of the Attorney-in-Fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the Attorney-in-Fact may approve in the Attorney-in-Fact's discretion.

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and revocation, hereby ratifying and confirming all Pbe done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing Attorney-in-Fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

The undersigned agrees that the Attorney-in-Fact may rely entirely on information furnished orally or in writing by the undersigned to the Attorney-in-Fact. The undersigned also agrees to indemnify and hold harmless the Company and the Attorney-in-Fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based on any untrue statement or omission of necessary facts in the information provided by the undersigned to the Attorney-in-Fact for purposes of executing, acknowledging, delivering and filing Forms 3, 4, or 5 (including amendments thereto) and agrees to reimburse the Company and the Attorney-in-Fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of, and transactions in securities issued by, the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of June, 2026.

By:_____/s/ Tao Fu_____
Name: Tao Fu